Peter Guenter - Merck CEO Board

MRK Stock  EUR 155.35  1.45  0.94%   

Insider

Peter Guenter is CEO Board of Merck Company
Age 61
Phone49 6151 72 0
Webhttps://www.merckgroup.com

Merck Management Efficiency

The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 7.93 B in total debt with debt to equity ratio (D/E) of 0.65, which is about average as compared to similar companies. Merck Company has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Min TangOrigin Agritech
61
James KangOrigin Agritech
54
Larry CordellOrigin Agritech
56
MBA MBASuperior Plus Corp
70
Amir KhoshniyatiIdentiv
N/A
Ash RajendraSuperior Plus Corp
N/A
Gengchen HanOrigin Agritech
58
David BullockOrigin Agritech
49
Jianxiong ZhengGuangzhou Baiyunshan Pharmaceut
53
Mike TaylorIdentiv
N/A
CCLP CMASuperior Plus Corp
62
Jun YangGuangzhou Baiyunshan Pharmaceut
53
Rick CarronSuperior Plus Corp
N/A
FCA FCASuperior Plus Corp
68
Geoffery MerszeiOrigin Agritech
68
Michael TrimbleOrigin Agritech
56
Justin ScarpullaIdentiv
50
Fei WangOrigin Agritech
40
Manfred MuellerIdentiv
53
James DevensSuperior Plus Corp
N/A
Steve DunlapIdentiv
N/A
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. MERCK KGAA operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 57850 people. Merck Company (MRK) is traded on Frankfurt Exchange in Germany and employs 63,723 people.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director
Matthias Heinzel, CEO Board
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Gerhard Schmitz, Head Accounting
Christine Seidman, Independent Director
Kathy Warden, Independent Director
Constantin Fest, Head Relations
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Peter Guenter, CEO Board
Barbara Weiland, Chief Officer
Belen MD, Chair CEO
Marcus Kuhnert, CFO Board
Peter Wendell, Independent Director
Friederike Rotsch, Group Compliance
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Dirk Toepfer, Chief Officer
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Franklin Clyburn, Executive Vice President Chief Commercial Officer
Rita Karachun, Senior Vice President - Finance, Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Kai Beckmann, CEO Board
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Bonds Directory
Find actively traded corporate debentures issued by US companies
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.